Effect of ZengmianFuzhengFormula combined with sacubitril/valsartan on chronic heart failure of deficiency of Qi and blood
Objective To observe the clinical efficacy of Zengmian Fuzheng Formula combined with sacubitril/valsartan on chronic heart failure(CHF)of deficiency of Qi and blood.Methods A total of 100 CHF patients(deficiency of Qi and blood)admitted to our hospital from December 2018 to June 2022 were selected as the research objects,and they were randomly assigned to the control group(sacubitril/valsartan,n =50)or observation group(ZengmianFuzhengFormula plus sacubitril/valsar-tan,n =50).After 8 weeks of treatment,the traditional Chinese medicine(TCM)symptoms scores(including palpitation,shortness of breath,fatigue,chest tightness,chest pain,pale complexion,spontaneous sweating,vertigo,tinnitus and edema),left ventricular remodeling indexes(LVRI)(including left ventric-ular end-diastolic diameter[LVEDD],left ventricular end-sys-tolic diameter[LVESD]and left ventricular ejection fraction[LVEF])and laboratory indexes(including platelet-to-lymphocyte ratio[PLR],neutrophil-to-lymphocyte ratio[NLR],N-terminal B-type natriuretic peptide[NT-proBNP]and prealbumin[PA])were included as comparators between groups before and after treatment.Theadverse reactions during treatment was observed between groups.Results The total effective rate in observation group was significantly higher than that of control group(90.00%[45/50]vs 72.00%[36/50],P<0.05).Af-ter treatment,the dimension score and total score of TCM symptoms scores in the two groups were significantly lower than those before treatment(P<0.05),especially in the observation group(P<0.05).After treatment,LVEDD and LVESD were signifi-cantly reduced(P<0.05),while LVEF were significantly increased(P<0.05),and the improvement was more significant in the observation group(P<0.05).After treatment,the levels of PLR,NLR and serum NT-proBNP in the peripheral blood of the two groups were significantly lower than those before treatment(P<0.05),but the level of serum PA was significantly higher(P<0.05),and the improvements were more significant in the observation group(P<0.05).The incidence of adverse reac-tions in the observation group was comparable to the control group(4.00%[2/50]vs 6.00%[3/50],P>0.05).Conclusion ZengmianFuzhengFormula combined with sacubitril/valsartan in the treatment of CHF patients with Qi and blood deficiency syndrome can effectively relieve symptoms and signs,reduce PLR and NLR in peripheral blood,regulate serum NT-proBNP and PA levels,and improve left ventricular remodeling.It improves nutritional status,inhibits LVRI,improves cardiac function,and does not increase the risk of adverse drug reactions,with good efficacy and high safety.
Chronic heart failureQi and blood deficiency syndromeIntegrative medicine therapy
NETL
NSTL
万方数据
